BACKGROUND AND AIMS: Crohn's disease (CD) is a chronic and invalidating inflammatory bowel disease of unknown etiology. The coordinated action of the cytochrome metabolizing subfamily CYP3A and the transport protein P-glycoprotein (P-gp) in the enterocyte results in a reduced bioavailability of drugs administered orally. Cytokines modulate the expression and functionality of CYP3A and P-gp. Although P-gp results are in disagreement between animal and Caco-2 cell studies, all authors report a decrease in CYP3A levels after exposure to proinflammatory agents. In humans, CYP3A and P-gp mRNA, protein, and functionality levels were higher in various tissues in patients with CD as compared with control groups. Our study's aim was to analyze the impact of systemic inflammation on the expression of CYP3A and P-gp in duodenal normal tissue. MATERIALS AND METHODS: We compared CYP3A and P-gp mRNA expression in 19 noninflamed duodenal biopsies from children with CD with 19 normal biopsies. We used a real-time reverse-transcription-polymerase chain reaction technique. RESULTS: There was a high variability in the expression of the 3 CYP3A isoforms and P-gp. CYP3A4, CYP3A5, and P-gp levels were significantly higher in the CD group than in the control group. DISCUSSION AND CONCLUSIONS: CYP3A and P-gp are involved in the metabolism and transport of many drugs prescribed in CD including corticosteroids. Changes occurring in their duodenal and hepatic expression may explain important interindividual differences in the bioavailability and response to treatment. Further explorations considering protein and activity must be undertaken to understand how such changes affect drug absorption and bioavailability.
BACKGROUND AND AIMS: Crohn's disease (CD) is a chronic and invalidating inflammatory bowel disease of unknown etiology. The coordinated action of the cytochrome metabolizing subfamily CYP3A and the transport protein P-glycoprotein (P-gp) in the enterocyte results in a reduced bioavailability of drugs administered orally. Cytokines modulate the expression and functionality of CYP3A and P-gp. Although P-gp results are in disagreement between animal and Caco-2 cell studies, all authors report a decrease in CYP3A levels after exposure to proinflammatory agents. In humans, CYP3A and P-gp mRNA, protein, and functionality levels were higher in various tissues in patients with CD as compared with control groups. Our study's aim was to analyze the impact of systemic inflammation on the expression of CYP3A and P-gp in duodenal normal tissue. MATERIALS AND METHODS: We compared CYP3A and P-gp mRNA expression in 19 noninflamed duodenal biopsies from children with CD with 19 normal biopsies. We used a real-time reverse-transcription-polymerase chain reaction technique. RESULTS: There was a high variability in the expression of the 3 CYP3A isoforms and P-gp. CYP3A4, CYP3A5, and P-gp levels were significantly higher in the CD group than in the control group. DISCUSSION AND CONCLUSIONS:CYP3A and P-gp are involved in the metabolism and transport of many drugs prescribed in CD including corticosteroids. Changes occurring in their duodenal and hepatic expression may explain important interindividual differences in the bioavailability and response to treatment. Further explorations considering protein and activity must be undertaken to understand how such changes affect drug absorption and bioavailability.
Authors: Souzan B Yanni; P Brian Smith; Daniel K Benjamin; Patrick F Augustijns; Dhiren R Thakker; Pieter P Annaert Journal: Biopharm Drug Dispos Date: 2011-03-30 Impact factor: 1.627
Authors: K L R Brouwer; L M Aleksunes; B Brandys; G P Giacoia; G Knipp; V Lukacova; B Meibohm; S K Nigam; M Rieder; S N de Wildt Journal: Clin Pharmacol Ther Date: 2015-09 Impact factor: 6.875
Authors: Miriam G Mooij; Ute I Schwarz; Barbara A E de Koning; J Steven Leeder; Roger Gaedigk; Janneke N Samsom; Edwin Spaans; Johannes B van Goudoever; Dick Tibboel; Richard B Kim; Saskia N de Wildt Journal: Drug Metab Dispos Date: 2014-05-14 Impact factor: 3.922
Authors: Célia Lloret Linares; Xavier Declèves; Jean Michel Oppert; Arnaud Basdevant; Karine Clement; Christophe Bardin; Jean Michel Scherrmann; Jean Pierre Lepine; Jean François Bergmann; Stéphane Mouly Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447